1502 GMT - Novo Nordisk's early trial data of amycretin impresses on weight loss, with patients losing 22% of their body weight at the highest dose at 36 weeks, Barclays analysts write. "Novo shares are taking this well as this news finally breaks the tide of negative sentiment." Though it was a phase 1 study with a multi-part design and there is limited information on safety, the weight loss puts it on par with the best injectable data out there, Barclays says. Shares trade 11% higher at 643.80 Danish kroner.(dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 24, 2025 10:02 ET (15:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。